Sarbjeet Sran, MD
Allergy & Immunology · Hickory, NCNPI 1528025723
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 327 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,285 and has fallen 70.3% since, to $678 in 2024.
Across 327 payments — averaging $25.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Sanofi$731
- Regeneron Healthcare Solutions, Inc.$616
- Alk-abello, Inc$359
- Pharming Healthcare, Inc.$334
- plus $3K from 23 others
What the payments were for
- Food & beverage$8,420100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $2,014 |
| GSK | 78 | $1,815 |
| Sanofi | 35 | $731 |
| Regeneron Healthcare Solutions, Inc. | 27 | $616 |
| Alk-abello, Inc | 10 | $359 |
| Pharming Healthcare, Inc. | 8 | $334 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $286 |
| Kaleo, Inc. | 14 | $242 |
| Genentech USA, Inc. | 12 | $224 |
| LEO Pharma Inc. | 4 | $183 |
| Biocryst US Sales Co., LLC | 9 | $183 |
| Optinose US, Inc. | 4 | $167 |
| Pfizer | 13 | $166 |
| Novartis | 3 | $126 |
| Amgen | 7 | $123 |
| Grifols USA, LLC | 8 | $123 |
| Covis Pharma GmbH | 7 | $107 |
| Phadia US Inc. | 2 | $103 |
| Circassia Inc. | 1 | $98 |
| CSL Behring | 5 | $94 |
| Octapharma USA, Inc. | 3 | $59 |
| Boehringer Ingelheim | 4 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Incyte Corporation | 2 | $41 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
| Merck | 2 | $29 |
| Shire North American Group Inc | 2 | $24 |
| USWM, LLC | 1 | $20 |
| Biocryst Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$484
- NUCALA$379
- TEZSPIRE$352
- DUPIXENT$234
- Xhance$125
- ADBRY$125
- TRELEGY ELLIPTA$116
- PRE-PEN$109
- Histatrol (histamine phosphate)$109
- Timothy Grass (phleum pratense)$109
- Dust mite (D. farinae)$109
- Alternaria alternate (Alternaria tenuis)$109
- RUCONEST$109
How this compares
$8,420 in reported general payments places this provider in the 60th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 23 | $94,654 |
| NucalaMepolizumab | 25 | $92,306 |
| TezspireTezepelumab-Ekko | 13 | $53,641 |
| Dupixent SyringeDupilumab | 14 | $53,522 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $43,576 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $20,629 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,894 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,888 |
| Wixela InhubFluticasone Propion/Salmeterol | 29 | $4,537 |
| Ipratropium Bromide | 78 | $3,806 |
| Fluticasone Propionate | 133 | $1,877 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $1,081 |
| Ventolin HfaAlbuterol Sulfate | 11 | $607 |
| Montelukast Sodium | 84 | $604 |
| Triamcinolone Acetonide | 32 | $311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $1,815 | $156,511137 claims |
| AstraZenecaTezspire, Symbicort | $2,014 | $58,52927 claims |
| Boehringer IngelheimCombivent Respimat | $58 | $5,89412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Hickory
- Maeve OconnorCharlotte$2.2M
- Joel HartmanWinston Salem$749K
- Cristine RadojicicDurham$558K
- Scott ComminsChapel Hill$555K
- William McCannAsheville$486K
- Aerik WilliamsSalisbury$298K
- Karen DunnRaleigh$258K
- Roopen PatelCharlotte$257K
- Jonathan RomeoRaleigh$230K
- John NorrisCharlotte$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.